CD36 Participates in PrP106–126-Induced Activation of Microglia

Abstract

Microglial activation is a characteristic feature of the pathogenesis of prion diseases. The molecular mechanisms that underlie prion-induced microglial activation are not very well understood. In the present study, we investigated the role of the class B scavenger receptor CD36 in microglial activation induced by neurotoxic prion protein (PrP) fragment 106–126 (PrP106–126). We first examined the time course of CD36 mRNA expression upon exposure to PrP106–126 in BV2 microglia. We then analyzed different parameters of microglial activation in PrP106–126-treated cells in the presence or not of anti-CD36 monoclonal antibody (mAb). The cells were first incubated for 1 h with CD36 monoclonal antibody to block the CD36 receptor, and were then treated with neurotoxic prion peptides PrP106–126. The results showed that PrP106–126 treatment led to a rapid yet transitory increase in the mRNA expression of CD36, upregulated mRNA and protein levels of proinflammatory cytokines (IL-1β, IL-6 and TNF-α), increased iNOS expression and nitric oxide (NO) production, stimulated the activation of NF-κB and caspase-1, and elevated Fyn activity. The blockade of CD36 had no effect on PrP106–126-stimulated NF-κB activation and TNF-α protein release, abrogated the PrP106–126-induced iNOS stimulation, downregulated IL-1β and IL-6 expression at both mRNA and protein levels as well as TNF-α mRNA expression, decreased NO production and Fyn phosphorylation, reduced caspase-1 cleavage induced by moderate PrP106–126 –treatment, but had no effect on caspase-1 activation after treatment with a high concentration of PrP106–126. Together, these results suggest that CD36 is involved in PrP106–126-induced microglial activation and that the participation of CD36 in the interaction between PrP106–126 and microglia may be mediated by Src tyrosine kinases. Our findings provide new insights into the mechanisms underlying the activation of microglia by neurotoxic prion peptides and open perspectives for new therapeutic strategies for prion diseases by modulation of CD36 signaling.

PPARγ-induced upregulation of CD36 enhances hematoma resolution and attenuates long-term neurological deficits after germinal matrix hemorrhage in neonatal rats

“…Furthermore, activated microglia/macrophages have two differentiated states, a pro-inflammatory classically activated state (M1), and an immune dampening and tissue regenerative alternatively activated state (M2) (Klebe et al, 2015). CD36 stimulation can contribute towards microglia/macrophage activation as well as M2 polarization (Chavez-Sanchez et al, 2014; Kouadir et al, 2012; Rios et al, 2013). PPARγ stimulation also polarizes microglia/macrophages towards the M2 state (Penas et al, 2015; Pisanu et al, 2014; Yoon et al, 2008).…”

Baicalin attenuates proinflammatory cytokine production in oxygen–glucose deprived challenged rat microglial cells by inhibiting TLR4 signaling pathway

“…Due to the demonstration of its broad pharmacological effects both in vivo and in vitro, baicalin has also been used to treat ischemic cerebral vascular disease via its neuronal It is well known that activated microglia become hypertrophic, undergo rapid proliferation and migrate to inflammatory sites where they produce excess amounts of neurotoxic and proinflammatory mediators that mediate neuronal damage [24,25]. Microglial activation results in their production of proinflammatory cytokines or chemokines such as IL-1β, IL-6, TNF-α, MIP-1α and MIP-1β [26][27][28]. While release of these factors typically prevents further damage to CNS tissue, they may also be toxic to neurons and other glial cells [29].…”

Insulin-associated neuroinflammatory pathways as therapeutic targets for traumatic brain injury

“…The interaction of the CD36 microglia with a prionic protein results in the expression of the pro-inflammatory cytokines, including CD36 mRNA, and SFK phosphorylation (50). The crosstalk between CD36 and Aβ can stimulate the production of ROS in microglia and macrophages, resulting in CNS recruitment of inflammatory cells (51,52).…”